Dosing & Uses
Dosage Forms & Strengths
uretral solution
- 30%
- 18% (dilute)
Retrograde Cystourethrography
Instill 25-300 mL into bladder depending on age of patient and degree of bladder irritability; amounts >300 mL may be used if bladder capacity allows; best results obtained when the bladder is filled with the contrast agent
Administration
After sterile catheterization, the bladder should be filled to capacity using suitable sterile administration set; avoid using excessive pressure; presence of bladder discomfort or reflux and/or spontaneous voiding usually indicates bladder is full
Dosage Forms & Strengths
uretral solution
- 30%
- 18% (dilute)
Retrograde Cystourethrography
Instill 25-300 mL into bladder depending on age of patient and degree of bladder irritability; amounts >300 mL may be used if bladder capacity allows; best results obtained when the bladder is filled with the contrast agent
Administration
After sterile catheterization, the bladder should be filled to capacity using suitable sterile administration set; avoid using excessive pressure; presence of bladder discomfort or reflux and/or spontaneous voiding usually indicates bladder is full
Adverse Effects
Frequency Not Defined
Hypothyroidism or transient thyroid suppression
With intravasation of drug
- Anaphylactoid reactions manifested as edema of the face and glottis, respiratory distress, confusion or shock that can be fatal
Warnings
Contraindications
Hypersensitivity to diatrizoate
Intravascular or intrathecal use
Cautions
Personal or family history of bronchial asthma, significant allergies, or previous reactions to contrast agents
Iodine sensitivity
Use intravascular techniques that minimize risk for extravasation
Use caution in hepatic impairment, heart failure, hypertension, multiple myeloma, hyperthyroidism, pheochromocytoma, renal impairment, sickle cell disease, subarachnoid hemorrhage, and thromboembolism
FDA MedWatch
- March 30, 2022: FDA recommended newborns and children aged ≤3 years have follow-up thyroid monitoring within 3 weeks after receiving iodinated contrast media (ICM) for X-rays and other medical imaging procedures
- Published studies found underactive thyroid and temporary decreases in thyroid hormone levels were uncommon; however, if identified and treated early, future complications may be prevented
- Appropriately monitor for signs and symptoms of hypothyroidism and decreased thyroid hormone levels following ICM exposure; consider evaluating thyroid function within 3 weeks, especially in term and preterm neonates and children with some underlying conditions
- If thyroid dysfunction detected, treat and monitor thyroid function as needed to avoid future complications
- Certain pediatric patients are at increased risk, including newborns or have very low birth weight, prematurity, or presence of cardiac or other conditions (eg, requiring care in neonatal or pediatric ICUs)
- Patients with cardiac conditions may be at greatest risk since they often require high doses of contrast during invasive cardiac procedures
Pregnancy & Lactation
Pregnancy Category: C
Lactation: Excreted in breast milk, use caution
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Provides contrast enhancement of the bladder
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| Gastrografin oral - | 66-10 % solution |  | |
| Gastrografin oral - | 66-10 % solution |  | |
| MD-Gastroview oral - | 66-10 % solution |  |
Copyright © 2010 First DataBank, Inc.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
